Integer Holdings earnings date
Want to see ITGR full AI Analyst Report?
Integer Holdings (ITGR) Q1 2026 Earnings Report
ITGR Q1 2026 EPS Results
- Actual EPS
- $1.20
- Consensus EPS
- $1.19
- Beat/Miss
- Beat by +$0.01
- One Year Ago EPS
- $1.31
ITGR Q1 2026 Revenue Results
- Actual Revenue
- $441.10M
- Expected Revenue
- $426.48M
- Beat/Miss
- Beat by +$14.62M
- YoY Revenue Growth
- +1.13%
Earnings Announcement Details
- Quarter
- Q1 2026
- Date
- 04/30/2026
- Time
- Before Open
- Conference Call
- Thursday, April 30, 2026
Integer Holdings's next earnings date is estimated for February 18, 2027, based on past reporting schedules.
Q1 2026 Earnings Call Audio
Q1 2026 Earnings Slide Deck
Q1 2026 Earnings Call Summary
The call conveyed a mixed picture: a modest top-line improvement in Q1 (reported +0.5%, organic +1.3%) and several strategic positives (share buybacks, lower interest expense, targeted cost actions, pipeline strength and a Board-initiated strategic review) were offset by meaningful near-term profitability pressures (adjusted operating income down 14%, margin contraction of 230 bps), weaker cash flow in Q1, and a downward revision to full-year 2026 revenue and profit guidance. Management characterizes the demand softness—primarily in electrophysiology—as temporary normalization and emphasized actions to protect long-term growth, but the guidance cuts and margin contraction represent notable near-term headwinds.
Integer updated its 2026 guidance with full‑year reported sales now expected at $1.805–$1.835 billion (down 1%–3% YoY) and organic sales flat to down 1% (including a ~3%–4% headwind from three new products; organic growth excluding those products ~3%–4%); inorganic decline ~1% (Portable Medical exit); C&V expected flat to down low‑single digits, CRM&N flat to up low‑single digits, and other markets down ~$34M–$36M. Profitability outlook: adjusted EBITDA $375M–$399M (down 1%–7%), adjusted operating income $285M–$305M (down 5%–11%) with sequential margin improvement expected (Q2 operating margin +80–140 bps and continuing improvement through 2026), adjusted net income $200M–$220M (down 3%–11%) and adjusted EPS $5.83–$6.40 (flat to down 9%). Cash/debt targets: cash flow from operations $185M–$205M (≈$15M lower at midpoint), CapEx $95M–$105M (~5%–6% of sales), free cash flow $85M–$105M, year‑end net total debt $1.185B–$1.205B and leverage expected in the 2.5x–3.5x trailing‑4Q adjusted EBITDA target range (Q1 net total debt $1.264B, leverage 3.2x). Q1 actuals and drivers: sales $440M (+0.5% reported, +1.3% organic), adjusted EBITDA $85M (‑7%), adjusted operating margin 13.9% (‑230 bps), adjusted net income $41M (‑10%), adjusted EPS $1.20 (‑8%), cash from ops $25M, CapEx $24M, free cash flow $1M; interest expense was $4M lower (helping EPS by ~$0.10), and share repurchases of $50M in Q4 ’25 (~700k shares) and $50M in Q1 ’26 (~600k shares) reduced weighted shares ~2% (adding ~$0.02 to EPS).
- Quarterly Revenue GrowthQ1 2026 sales of $440 million, up 0.5% on a reported basis and up 1.3% on an organic basis versus the prior year.
- Strength in Core Product Lines (C&V and CRM&N)Cardio & Vascular sales of $262 million, up 1% in Q1 and up 13% on a trailing 4-quarter basis to $1.110 billion driven by EP, acquisitions and Neurovascular demand. Cardiac Rhythm Management & Neuromodulation sales of $168 million, up 5% in Q1; trailing 4-quarter CRM&N sales up 2% to $677 million.
- Earnings Per Share Benefited from Lower Interest and BuybacksAdjusted EPS of $1.20 in Q1; benefited from $4 million lower interest expense (added approximately $0.10 per share) and share repurchases (completed $50 million in Q4 2025 and $50 million in Q1 2026, reducing weighted average shares ~2% and adding ~$0.02 to EPS).
- Targeted Cost Actions and Margin Recovery PlanCompany is implementing additional near-term cost reduction actions (designed not to compromise customer service or long-term growth) and expects Q2 adjusted operating income margin to improve 80–140 basis points sequentially with margins improving throughout 2026.
- Balance Sheet Discipline and Leverage in Target RangeNet total debt of $1.264 billion (up $74 million QoQ) yields a net total debt leverage of 3.2x trailing 4-quarter adjusted EBITDA, which is inside the company’s strategic target range of 2.5x–3.5x.
- Strategic Review Initiated to Maximize Shareholder ValueBoard initiated a strategic review in response to heightened interest; review may consider a range of alternatives while management reiterates confidence in the stand‑alone strategy and long-term objectives.
- Long-Term Market Position and PipelineManagement reiterates confidence in attractive med-tech end markets (target market growth 4%–6%), a robust new product pipeline and the expectation to return to organic sales growth ~200 basis points above market in 2027.
- Cash Deployment and Capital PlanContinued share repurchases (totaling ~$100 million across Q4 2025 and Q1 2026) and guidance for 2026 CapEx of $95–105 million (~5%–6% of sales), with expected free cash flow of $85–105 million for the year.
ITGR Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 18, 2027 | 2026 (Q4) | 1.60- | 1.76 | ― | ― |
| Oct 29, 2026 | 2026 (Q3) | 1.681.34 | 1.79 | -25.14% (-0.45) | |
| Aug 03, 2026 | 2026 (Q2) | 1.381.60 | 1.55 | 3.23% (+0.05) | |
| Apr 30, 2026 | 2026 (Q1) | 1.191.20 | 1.31 | -8.40% (-0.11) | |
| Feb 19, 2026 | 2025 (Q4) | 1.701.76 | 1.43 | 23.08% (+0.33) | |
| Oct 24, 2025 | 2025 (Q3) | 1.691.79 | 1.43 | 25.17% (+0.36) | |
| Jul 24, 2025 | 2025 (Q2) | 1.551.55 | 1.3 | 19.23% (+0.25) | |
| Apr 24, 2025 | 2025 (Q1) | 1.231.31 | 1.14 | 14.91% (+0.17) | |
| Feb 20, 2025 | 2024 (Q4) | 1.461.43 | 1.39 | 2.88% (+0.04) | |
| Oct 24, 2024 | 2024 (Q3) | 1.361.43 | 1.27 | 12.60% (+0.16) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


